HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Pentoxifylline as an ancillary treatment for severe falciparum malaria in Thailand.

Abstract
Pentoxifylline, an inhibitor of tumor necrosis factor, has been evaluated as an antimalarial agent in combination with artesunate in 45 patients with severe falciparum malaria. Patients were admitted to the intensive care unit at the Hospital for Tropical Diseases in Bangkok, Thailand, and randomly assigned to treatment for 72 hr with a combination of intravenously administered artesunate and 1) placebo, 2) low-dose pentoxifylline (0.83 mg/kg/hr), or 3) high-dose pentoxifylline (1.67 mg/kg/hr). All 45 patients had one or more manifestations of severe malaria such as cerebral malaria (n = 18), renal failure requiring hemodialysis (n = 9), azotemia (n = 8), jaundice (n = 25), or hyperparasitemia (n = 30). The overall severity was comparable in the three groups. Clinical outcome was assessed with respect to the parasite clearance time and the fever clearance time in all patients. In addition, a number of subsidiary outcome variables were examined in specific subgroups, including the recovery time from coma for patients with cerebral malaria, the duration of intubation in patients with respiratory distress, the number of hemodialysis treatments needed for patients with acute renal failure, and the number of units of blood administered to patients requiring transfusion. Concentrations of tumor necrosis factor were reduced in all three groups at 48 hr after treatment. No significant differences among the three treatment groups were found for any of the outcome variables examined. We conclude that the addition of pentoxifylline to artesunate therapy for severe malaria produced no evident clinical benefit.
AuthorsS Looareesuwan, P Wilairatana, S Vannaphan, V Wanaratana, C Wenisch, M Aikawa, G Brittenham, W Graninger, W H Wernsdorfer
JournalThe American journal of tropical medicine and hygiene (Am J Trop Med Hyg) Vol. 58 Issue 3 Pg. 348-53 (Mar 1998) ISSN: 0002-9637 [Print] United States
PMID9546417 (Publication Type: Clinical Trial, Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't, Research Support, U.S. Gov't, P.H.S.)
Chemical References
  • Antimalarials
  • Artemisinins
  • Phosphodiesterase Inhibitors
  • Sesquiterpenes
  • Artesunate
  • Pentoxifylline
Topics
  • Adolescent
  • Adult
  • Antimalarials (therapeutic use)
  • Artemisinins
  • Artesunate
  • Drug Therapy, Combination
  • Female
  • Humans
  • Malaria, Falciparum (complications, drug therapy)
  • Male
  • Middle Aged
  • Pentoxifylline (therapeutic use)
  • Phosphodiesterase Inhibitors (therapeutic use)
  • Sesquiterpenes (therapeutic use)
  • Thailand

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: